Lymphoma & CLL Trials

Tisagenlecleucel receives EC approval for the treatment of relapsed or refractory follicular lymphoma

This is the third indication tisagenlecleucel has been approved for in the EU and the first CAR...

FDA grants priority review to tisagenlecleucel for relapsed/refractory follicular lymphoma

On October 27, 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) had accepted a...

Two-year follow-up of TRANSCEND NHL 001 suggests lisocabtagene maraleucel maintains a durable response in R/R large B-cell lymphoma

Liso-cel demonstrated durable remission rates and a promising safety...

Positive effect on HRQoL and symptom severity with liso-cel in patients with R/R LBCL

Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for the...

ZUMA-12 primary analysis: Axi-cel for the frontline treatment for high-risk LBCL

The primary analysis of the ZUMA-12 phase II trial suggests that axi-cel has potential as a safe and effective option...

ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

Lisocabtagene maraleucel receives European Commission approval as ≥ third-line treatment for certain forms of relapsed or refractory large B-cell lymphoma

Liso-cel is a CD19-directed chimeric antigen...

Outpatient administration of liso-cel: Preliminary results from the OUTREACH study

Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...